Action Compass Pathways - 5Y6

Compass Pathways Plc (5Y6) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

11,70

( -5,65% )

Prix Achat

11,50

Prix Vente

11,80

Volume échangé

7 239

11,60 Fourchette du Jour 12,60

0,00 Plage de 52 semaines 0,00

Clôture Veille

12,40

Ouverture

12,50

Dernière Transaction

104

11.6

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways announces second quarter 2024 financial results and business highlights Top-line COMP005 data for COMP360 phase 3 pivotal program...

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways appoints Lori Englebert as Chief Commercial Officer New executive appointment made ahead of pivotal study results, potential...

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights COMP360 phase 3 pivotal program in...

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic...

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective...

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery...

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David...

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE...

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for...

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement Three-year research collaboration will investigate...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

5Y6 - Frequently Asked Questions (FAQ)

What is the current Compass Pathways Plc share price?

The current share price of Compass Pathways Plc is 11,70 €

What is the 1 year trading range for Compass Pathways Plc share price?

Compass Pathways Plc has traded in the range of 0,00 € to 0,00 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Compass Pathways Plc (5Y6)

Compass Pathways Plc (5Y6) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

5Y6 Dernières nouvelles

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

5Y6 - Frequently Asked Questions (FAQ)

5Y6 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Compass Pathways Plc (5Y6)

Compass Pathways Plc (5Y6) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

5Y6 Dernières nouvelles

Compass Pathways announces second quarter 2024 financial results and business highlights

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

5Y6 - Frequently Asked Questions (FAQ)

5Y6 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE